Halozyme Therapeutics, Inc.
HALO
$38.57
$0.110.29%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 85.39M | 81.84M | 74.75M | 39.62M | 57.70M |
| Total Depreciation and Amortization | 20.69M | 20.58M | 20.63M | 20.46M | 7.11M |
| Total Amortization of Deferred Charges | 1.83M | 1.82M | 1.82M | 1.84M | 1.83M |
| Total Other Non-Cash Items | 20.54M | 6.09M | 18.12M | 11.24M | 20.88M |
| Change in Net Operating Assets | -26.10M | 22.09M | -48.48M | 13.81M | -5.08M |
| Cash from Operations | 102.35M | 132.41M | 66.84M | 86.96M | 82.45M |
| Capital Expenditure | -2.60M | -2.94M | 1.62M | -11.38M | -2.34M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 9.99M |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.70M | -80.51M | 53.37M | -48.79M | -9.39M |
| Cash from Investing | -8.29M | -83.45M | 54.99M | -60.16M | -1.75M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | -13.48M | 0.00 |
| Issuance of Common Stock | 2.38M | 4.10M | 2.45M | -- | 6.97M |
| Repurchase of Common Stock | -252.30M | 0.00 | -- | -151.13M | -1.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -639.00K |
| Cash from Financing | -249.92M | 4.10M | 2.45M | -164.61M | 6.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -155.86M | 53.06M | 124.28M | -137.81M | 87.04M |
